Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.60 |
| ▸ | FNTB | P49356 | 5/20 | 0.60 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.60 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14554164 | 1.00 | FNTA (0.60) | FNTAFNTBPGGT1BFOLH1NOD1 | |
| SCHEMBL9830511 | 0.90 | NOD1 (0.60) | FNTAFNTBPGGT1BFOLH1NOD1 | |
| SCHEMBL9830509 | 0.90 | NOD1 (0.60) | FNTAFNTBPGGT1BFOLH1NOD1 | |
| SCHEMBL24961510 | 0.89 | FNTA (0.62) | FNTAFNTBPGGT1BFOLH1NOD1 | |
| SCHEMBL6136379 | 0.89 | NOD1 (0.68) | FNTAFNTBPGGT1BNOD1MAPK1 | |
| SCHEMBL6136376 | 0.89 | NOD1 (0.68) | FNTAFNTBPGGT1BNOD1MAPK1 | |
| SCHEMBL4741211 | 0.87 | NOD1 (0.70) | FNTAFNTBPGGT1BNOD1MAPK1 | |
| SCHEMBL542916 | 0.87 | NOD1 (0.70) | FNTAFNTBPGGT1BNOD1MAPK1 | |
| SCHEMBL25264982 | 0.87 | NOD1 (0.70) | FNTAFNTBPGGT1BNOD1MAPK1 | |
| SCHEMBL17204611 | 0.87 | NOD1 (0.70) | FNTAFNTBPGGT1BNOD1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623338-B2 | Methionine-derived peptidomimetics and their use in the protection of mitochondria of cutaneous cells | EXSYMOL S.A.M. (MC) | 2014-01-07 | — | — | US | disclosed |
| EP-2431356-B1 | Peptidomimetic methionine derivatives as well as their use in the protection of skin cells | EXSYMOL SA (MC) | 2013-11-13 | — | — | EP | disclosed |
| US-20120070394-A1 | METHIONINE-DERIVED PEPTIDOMIMETICS AND THEIR USE IN THE PROTECTION OF MITOCHONDRIA OF CUTANEOUS CELLS | EXSYMOL S.A.M. (MC) | 2012-03-22 | — | — | US | disclosed |
| EP-2431356-A1 | Peptidomimetic methionine derivatives as well as their use in the protection of skin cells | Exsymol S.A.M. (MC) | 2012-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070394-A1 | METHIONINE-DERIVED PEPTIDOMIMETICS AND THEIR USE IN THE PROTECTION OF MITOCHONDRIA OF CUTANEOUS CELLS | MTR, ARG2, MARS2 | FNTA 4498/4885FNTB 3825/4885PGGT1B 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.